- Advertisement -
Australian medicinal cannabis company AusCann (ASX: AC8) today announced it is preparing a trial of its proprietary cannabinoid-based formulations in people with spinal cord injury (SCI).
The company, which acquired CannPal Animal Therapeutics for $17.5 million earlier this year, has commenced…

